Amrinone, also known as inamrinone, and sold as Inocor, is a pyridine phosphodiesterase 3 inhibitor. [1] It is a drug that may improve the prognosis in patients with congestive heart failure. [2]

Feb 29, 2024 · Inamrinone, also known as amrinone, is a drug that increases cardiac output through its positive inotropic and vasodilatory effects. It is prescribed for the short-term management of congestive heart failure, relieving symptoms of CHF such as fatigue, weakness, edema, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.

Jul 24, 2007 · Amrinone is a positive inotropic agent and phosphodiesterase inhibitor used in the management of treatment of congestive heart failure.

Inamrinone is a prescription medication used for the treatment of congestive heart failure.

Medscape - Indication-specific dosing for amrinone (inamrinone), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...

Amrinone is a novel, nonadrenergic cardiac stimulant that improves myocardial contractility while inducing vasodilation. Its mechanism of action appears to be direct inhibition of phosphodiesterase; the result of this is increased intracellular cAMP activity, an action that increases transmembrane calcium flux, potentiating cardiac chronotropy ...

Mar 25, 2025 · Inamrinone Injection USP represents a new class of cardiac inotropic agents distinct from digitalis glycosides or catecholamines. Inamrinone lactate is designated chemically as 5-Amino [3,4'-bipyridin]-6 (1 H)-one 2-hydroxypropanate and has the following structure:

Aug 2, 2013 · Amrinone has been a great forerunner of noncatechol and nonglycoside novel cardiotonic agents and given an extraordinary strong impact in the development of novel cardiotonic agents.

Inamrinone, also known as amrinone, is a drug that increases cardiac output through its positive inotropic and vasodilatory effects. It is prescribed for the short-term management of congestive heart failure, relieving symptoms of CHF such as fatigue, weakness, edema, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.

Sep 8, 2022 · Amrinone is an Inotropic agent belonging to Phosphodiesterase Enzyme Inhibitor. Amrinone is approved for the treatment of the short-term management of congestive heart failure, relieving symptoms of the condition such as fatigue, weakness, edema, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.